Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics Paragon

Cofactor Genomics has launched Paragon, a cancer type-agnostic solid tumor immune-profiling assay that uses a proprietary database of immune reference signatures to interrogate immune activity associated with disease or therapy response. For example, the assay can differentiate cells such as M1 and M2 macrophages and can report cancer-specific expression signals from genes including PD-1, PD-L1, and CTLA4. The assay requires only two FFPE tissue sections for analysis and can accommodate any solid tumor specimen, with expression databases pre-built for more than 25 different cancer types, Cofactor said.
The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.